Regulatory AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer BioSpaceDecnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer.HematologyRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioSpace Decnupaz is the first antibody-drug conjugate for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare and aggressive blood cancer. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: GSK hails ‘unprecedented’ cure rates with hep B drug Related Stories Regulatory FDA delays verdict on AZ breast cancer drug pharminent May 27, 2026 Regulatory Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC pharminent May 26, 2026 Regulatory Bayer gets swift review for Kerendia in type 1 diabetes pharminent May 21, 2026
